Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02753764 · ClinicalTrials.gov registry record · Phase 2
Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma
A Phase 2 study, sponsored by National Jewish Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02753764 is a Phase 2 study that has completed, run by National Jewish Health. The registered enrollment target is 2 participants.
The verdict
NCT02753764, a Phase 2 study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a double-blind, placebo controlled 4 week crossover study to investigate the efficacy and safety of AZD7624 (an inhaled p38 inhibitor) in corticosteroid resistant (CR) asthmatics. For the purpose of this study 10 symptomatic CR asthma patients with a FEV1% predicted \<80% and normal bronchodilator response, 10 CS asthmatics and 10 healthy controls will be recruited.
Interventions
- DRUG Placebo
- DRUG prednisone
- DRUG AZD7624
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02753764
The ClinicalTrials.gov registry entry for NCT02753764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02753764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02753764 about?
NCT02753764 is a clinical study titled "Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma". This is a double-blind, placebo controlled 4 week crossover study to investigate the efficacy and safety of AZD7624 (an inhaled p38 inhibitor) in corticosteroid resistant (CR) asthmatics. For the purpose of this study 10 symptomatic CR asthma patients with a FEV1% predicted \<80% and normal bronchod...
What is the current status of trial NCT02753764?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-01. Estimated completion is 2019-02-25.
What interventions are being tested in trial NCT02753764?
The interventions under investigation include: Placebo (DRUG), prednisone (DRUG), AZD7624 (DRUG).
Who is sponsoring clinical trial NCT02753764?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.